Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NETWORK 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 42Cytarabine 33Methotrexate 31Vincristine 27Filgrastim 26Etoposide 24Radiotherapy 19Peripheral Blood Stem Cell Transplantation 18Dexamethasone 18fludarabine phosphate 16Leucovorin 16Mercaptopurine 15Asparaginase 15Daunorubicin 14Prednisone 13merphos 12Doxorubicin 12Cyclosporine 11pegaspargase 10Vorinostat 10Rituximab 10Busulfan 10tanespimycin 9Ifosfamide 9Bortezomib 9Methylprednisolone 8Hydrocortisone 8Calcium Dobesilate 8fludarabine 7Tacrolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Leyk × Clear all
NCT00720109 2020-04-13

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2/3 Completed
63 enrolled 13 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡